PE130699A1 - IMIDAZOYLALKYL SUBSTITUTED WITH A FIVE, SIX OR SEVEN MEMBER HETERO-CYCLIC RING CONTAINING A NITROGEN ATOM - Google Patents

IMIDAZOYLALKYL SUBSTITUTED WITH A FIVE, SIX OR SEVEN MEMBER HETERO-CYCLIC RING CONTAINING A NITROGEN ATOM

Info

Publication number
PE130699A1
PE130699A1 PE1998001072A PE00107298A PE130699A1 PE 130699 A1 PE130699 A1 PE 130699A1 PE 1998001072 A PE1998001072 A PE 1998001072A PE 00107298 A PE00107298 A PE 00107298A PE 130699 A1 PE130699 A1 PE 130699A1
Authority
PE
Peru
Prior art keywords
alkyl
trihalometile
nitrogen atom
ring containing
member hetero
Prior art date
Application number
PE1998001072A
Other languages
Spanish (es)
Inventor
John J Piwinski
Robert G Aslanian
Wayne D Vaccaro
Daniel M Solomon
Stuart B Rosenblum
Ronald L Wolin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE130699A1 publication Critical patent/PE130699A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, X ES ALQUILO C1-C7, ALQUENO O ALQUILENO C2-C4 OPCIONALMENTE SUSTITUIDOS CON R7; n ES 0-2; m ES 0-4; p ES 0-4; CUANDO m ES 0-4; Y ES -SO2-, -CS-, -CO-, -CONR5-, -CO(CH2)wO-, ENTRE OTROS; w ES 1-4; CUANDO m ES 2-4, Y ES TAMBIEN -COR5-, -O-, -NR5CONR5, -CSNR2, ENTRE OTROS; R5 ES H, ALQUILO O BENCILO; R6 ES ARILO, HETEROARILO, HETEROCICLO DE 3-7 MIEMBROS, ARILO SUSTITUIDO CON 1-3 ALQUILO, HALOGENO, TRIHALOMETILO, CN, OR10, NO2, NR10R11; R10 Y R11 SON H, ALQUILO O TRIHALOMETILO; CUANDO Y ES -SO2-, R6 ES ADEMAS ALQUILO C1-C7, NR10R11; R1 ES H, ALQUILO, TRIHALOMETILO; R7 ES H, ALQUILO, TRIHALOMETILO, CN, NO2, OR10R11. TAMBIEN SE REFIERE A UN COMPUESTO PREFERIDO DE FORMULA Ia, ENTRE OTROS. Y A UNA COMPOSICION QUE COMPRENDE ADEMAS UN ANTAGONISTA DEL RECEPTOR DE HISTAMINA H1 COMO LORATADINA, DESCARBOETOXILORATADINA, FEXOFENADINA, CETIRIZINA. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR H3 Y PUEDE SER UTIL PARA TRATAR ALERGIA, INFLAMACION, ENFERMEDADES CARDIOVASCULARES, HIPOTENSION, GLAUCOMA, DESORDENES DEL SUENO, ENFERMEDADES DEL TRACTO GASTROINTESTINAL, HIPO E HIPER ACTIVIDAD DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA, OBESIDAD Y MIGRANAIT REFERS TO A COMPOUND OF FORMULA I, X IS ALKYL C1-C7, ALQUENE OR ALKYLENE C2-C4 OPTIONALLY REPLACED WITH R7; n ES 0-2; m is 0-4; p ES 0-4; WHEN m IS 0-4; Y IS -SO2-, -CS-, -CO-, -CONR5-, -CO (CH2) wO-, AMONG OTHERS; w IS 1-4; WHEN m IS 2-4, AND IS ALSO -COR5-, -O-, -NR5CONR5, -CSNR2, AMONG OTHERS; R5 IS H, ALKYL OR BENZYL; R6 IS ARYL, HETEROARYL, 3-7 MEMBER HETERO-CYCLE, ARYL SUBSTITUTED WITH 1-3 ALKYL, HALOGEN, TRIHALOMETILE, CN, OR10, NO2, NR10R11; R10 AND R11 ARE H, ALKYL OR TRIHALOMETILE; WHEN AND IS -SO2-, R6 IS ALSO C1-C7-ALKYL, NR10R11; R1 IS H, ALKYL, TRIHALOMETILE; R7 IS H, ALKYL, TRIHALOMETILE, CN, NO2, OR10R11. IT ALSO REFERS TO A PREFERRED COMPOUND OF FORMULA Ia, AMONG OTHERS. AND TO A COMPOSITION FURTHER COMPRISING A HISTAMINE H1 RECEPTOR ANTAGONIST LORATADINE, DECARBOETOXYLORATADINE, PHEXOPHENADINE, CETIRIZINE. COMPOUND I IS AN ANTAGONIST FOR THE H3 RECEPTOR AND MAY BE USEFUL FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASES, HYPOTENSION, GLAUCOMA, DISEASES OF THE GASTROINTESTINAL TRACT, HIPO EISTOS, HIPO OBESITY AND MIGRAN

PE1998001072A 1997-11-07 1998-11-06 IMIDAZOYLALKYL SUBSTITUTED WITH A FIVE, SIX OR SEVEN MEMBER HETERO-CYCLIC RING CONTAINING A NITROGEN ATOM PE130699A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96575497A 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
PE130699A1 true PE130699A1 (en) 1999-12-16

Family

ID=25510440

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001072A PE130699A1 (en) 1997-11-07 1998-11-06 IMIDAZOYLALKYL SUBSTITUTED WITH A FIVE, SIX OR SEVEN MEMBER HETERO-CYCLIC RING CONTAINING A NITROGEN ATOM

Country Status (12)

Country Link
EP (1) EP1028956A1 (en)
JP (1) JP2001522845A (en)
KR (1) KR20010031839A (en)
CN (1) CN1285828A (en)
AR (1) AR016671A1 (en)
AU (1) AU1296799A (en)
CA (1) CA2309609A1 (en)
HU (1) HUP0102662A3 (en)
IL (1) IL135727A0 (en)
PE (1) PE130699A1 (en)
WO (1) WO1999024421A1 (en)
ZA (1) ZA9810186B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
FR2827863A1 (en) * 2001-07-27 2003-01-31 Sanofi Synthelabo New dihydropyrrolyl alkyl imidazole derivatives having histamine receptor antagonist activity for treatment of obesity, diabetes, and central nervous system disorders
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
WO2005058823A1 (en) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
KR101287955B1 (en) * 2004-12-30 2013-07-23 얀센 파마슈티카 엔.브이. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2022175384A1 (en) * 2021-02-17 2022-08-25 Fundación Universidad Católica De Valencia San Vicente Mártir Small-molecule agents with antiviral activity against rna viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW268950B (en) * 1991-12-18 1996-01-21 Schering Corp
DK0619818T3 (en) * 1991-12-18 1996-11-25 Schering Corp Imidazoylalkyl substituted with a six-membered nitrogen-containing heterocyclic ring
AU7823894A (en) * 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
PE100298A1 (en) * 1996-08-16 1999-01-11 Schering Corp TREATMENT OF ALLERGIC RESPONSES OF THE SUPERIOR RESPIRATORY TRACT

Also Published As

Publication number Publication date
HUP0102662A3 (en) 2003-01-28
JP2001522845A (en) 2001-11-20
WO1999024421A1 (en) 1999-05-20
HUP0102662A2 (en) 2001-12-28
CN1285828A (en) 2001-02-28
AU1296799A (en) 1999-05-31
EP1028956A1 (en) 2000-08-23
ZA9810186B (en) 1999-05-06
IL135727A0 (en) 2001-05-20
CA2309609A1 (en) 1999-05-20
KR20010031839A (en) 2001-04-16
AR016671A1 (en) 2001-07-25
WO1999024421A8 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
PE20030417A1 (en) DERIVATIVES OF UREA AS ANTAGONISTS OF THE VAINILLOID RECEPTOR
PE130699A1 (en) IMIDAZOYLALKYL SUBSTITUTED WITH A FIVE, SIX OR SEVEN MEMBER HETERO-CYCLIC RING CONTAINING A NITROGEN ATOM
PE20030385A1 (en) UREA COMPOUNDS AS ANTAGONISTS OF NEUROPEPTIDE Y5 RECEPTORS AND
CY1119906T1 (en) POLYMERIC CONNECTORS OF OPTIONAL COMPETITORS
EA200301213A1 (en) 5-HT RECEPTOR LIGANDS AND THEIR APPLICATION
AR019626A1 (en) RECEIVING ANTAGONISTS Y5 OF NEUROPEPTIDES.
PE20011258A1 (en) BENZOCYCLOALKYLENYLAMINE DERIVATIVES AS ANTAGONISTS OF MUSCARINAL RECEPTORS
PE20021094A1 (en) SUBSTITUTE CYCLOHEXANE-1,4-DIAMINE DERIVATIVES
CY1107281T1 (en) TROPANI PRODUCTS Substituted with Ididazopyridine with CCR5 Antagonist Activity Receptor for HIV and Inflammation Therapy
PE20081314A1 (en) NON-STEROIDAL FUSED TRICYCLIC COMPOUNDS AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1 AND / OR NF-kB ACTIVITY
CY1108792T1 (en) DIOXANEI-2-ALKYLCARBAMIC PRODUCTS, THEIR PREPARATION AND THEIR APPLICATION
CY1106424T1 (en) N-PHENYL-PYRROLE GUANIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR BINDERS
TR200102411T2 (en) Hap-carrier conjugates for the prevention and treatment of nicotine addiction.
PE20050080A1 (en) OPIOID RECEPTOR ANTAGONISTS
DE69820632D1 (en) 2-PHENYL SUBSTITUTED 1- (N-PHENYLAMINOALKYL) PIPERAZINE DERIVATIVES
CY1107505T1 (en) NURSING COMPOUNDS AND THEIR USES AS CANNIVOID CONTAINERS
RU2007148217A (en) Preparation of N-phenyl-2-pyrimidinamine derivatives
CY1105078T1 (en) COMPETITORS TECH
DE69508093D1 (en) SUBSTITUTED PIPERIDINE FOR THE TREATMENT OF ALLERGIC DISEASES
PE20021097A1 (en) CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES
AR057056A1 (en) PROCESS FOR SYNTHESIS OF IMIDAZOL BENCILAMINAS
EA200500146A1 (en) MONOETHANESULPHONATE 3-Z- [1-4- (N - ((4-METHILPIPERAZIN-1-IL) METHYL CARBONYL) -N-METHYLAMINO) ANILINO) -1-FENYLMETHYLENE] -6-METHOXYCARBONYL-2-INDONONEONONEANONONEONONEANONONEONONEONEONONEONONEONEONONEONONEONONEONONEONONEONEONONEONONEONONEONONERO. PHARMACEUTICAL COMPOSITION
EA200201119A1 (en) LIGANDS OF MELANOCORTIN RECEPTORS
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
AR003429A1 (en) CRF RECEPTOR ANTAGONISTS, COMPOSITIONS CONTAINING THEM AND THE USE FOR THE MANUFACTURE OF MEDICINES.

Legal Events

Date Code Title Description
FC Refusal